Cardiorespiratory exercise testing before and during lung cancer treatment
Official title: Assessment of Respiratory Parameters and Physical Performance in Patients With Lung Cancer Qualified for Oncological Treatment Before and During Therapy, With Special Consideration of Cardiovascular Risk: A Cardiopulmonary Exercise Testing Study
Run by Medical University of Bialystok · NCT07529145 · Data updated 2026-11-12
This project tests whether a supervised exercise test (CPET) can measure heart and lung fitness in adults with lung cancer who are able to exercise (WHO/ECOG 0-2) before and during their treatment.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 90 (estimated) |
| Sponsor | Medical University of Bialystok Academic / other |
| Locations | 1 site (Bialystok, Podlaskie Voivodeship) |
| Status | Recruiting |
| Started | January 1, 2026 |
| Main results expected | March 1, 2027 |
| Study ends | September 1, 2027 |
| Registry record updated | April 14, 2026 |
| Trial ID | NCT07529145 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with histologically confirmed lung cancer of any stage who are scheduled for standard surgical or systemic treatment and have WHO/ECOG performance status 0–2 and the ability to perform CPET.
✕Probably not a fit
Patients with unstable cardiac disease, severe uncontrolled respiratory problems, resting oxygen saturation ≤85%, or any condition preventing safe exercise are excluded and unlikely to benefit from CPET here.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective observational project enrolls adults with histologically confirmed lung cancer who are planned for standard oncological management and can perform exercise. Participants undergo a supervised cardiopulmonary exercise test (CPET) before treatment start and again after the early phase of therapy or surgery to measure VO2peak, ventilatory efficiency, and integrated cardiorespiratory responses. All oncological treatments follow routine clinical care and CPET is the only study-specific procedure. The study is conducted at a tertiary university hospital in Bialystok with planned enrollment of about 90 consecutive patients.
Why it matters
Potential benefit: If successful, CPET could identify patients with low physiological reserve so clinicians can tailor monitoring and supportive care to reduce treatment complications.
How similar studies have gone: Similar CPET approaches have been used and shown predictive value for surgical risk and treatment tolerance, though prospective data across the course of standard oncological therapy are relatively limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Histologically confirmed lung cancer (any stage) * Qualified for standard oncological management (surgery and/or systemic therapy) * WHO/ECOG performance status 0-2 * Ability to perform cardiopulmonary exercise testing (CPET) * Written informed consent Exclusion Criteria: * Unstable ischemic heart disease * Symptomatic cardiac arrhythmias * Myocarditis or pericarditis * Decompensated heart failure * Active deep vein thrombosis * Suspected aortic dissection or severe aortic stenosis * Poorly controlled asthma * Resting oxygen saturation ≤ 85% on room air * Clinically relevant treatment-related adverse events above mild intensity (as applicable) * Any medical condition that, in the investigator's opinion, precludes safe participation in CPET * Withdrawal of informed consent
Where it's running
-
University Clinical Hospital in Bialystok, II Department of Pulmonology, Lung Cancer and Internal Medicine, Medical University of Bialystok
Bialystok, Podlaskie Voivodeship, Poland Recruiting
Study contacts
- Study coordinator: Klaudia Jadczak, Medical Doctor
- Email: klaudia.jadczak@sd.umb.edu.pl
- Phone: +48608726832
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Quality of life during adjuvant immunotherapy for locally advanced non-small cell lung cancer
This study looks at how patients feel and cope during a year of immunotherapy after chemoradiotherapy for locally advanced non-small cell lung cancer.
-
Long-term survival and AI-based prediction in NSCLC patients treated with immunotherapy
This study tests whether AI analysis of routine pathology images, along with multi-omics data, can predict long-term survival for people with advanced NSCLC treated with immunotherapy.
-
Fiber-Boost: High-fiber diet with immunotherapy for advanced non-small cell lung cancer
This trial will test whether adding a high-fiber diet to first-line immunotherapy helps adults with advanced non-small cell lung cancer and how it changes the gut bacteria and immune response.
-
AVA6103 for advanced or metastatic FAP-positive solid tumors
This study will test whether the experimental IV drug AVA6103 is safe and can help adults with advanced or metastatic FAP-positive cancers such as pancreatic, gastric/GEJ, cervical, or vulvar adenocarcinomas.
-
Tarlatamab with carboplatin/etoposide and atezolizumab for EGFR‑mutant lung adenocarcinoma that changed into small cell lung cancer
This trial tests whether adding tarlatamab to standard platinum‑etoposide chemotherapy and atezolizumab helps patients whose EGFR‑mutant lung adenocarcinoma has transformed into small cell lung cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.